Scientific Evidence For Cannabis Rescheduling Difficult To Challenge, Says Sklamberg

Howard Sklamberg, Life Sciences & Healthcare Regulatory partner, was quoted in Medscape and MarketWatch regarding the U.S. Department of Health and Human Services' (HHS) recommendation to move cannabis from Schedule I to Schedule III on the controlled substances list, which was issued in August of this year and sits with the U.S. Drug Enforcement Administration (DEA).

Newly released documents of the HHS' recommendation illustrate that the U.S. Food and Drug Administration (FDA) has determined that cannabis has a legitimate medical use and should thus be moved from Schedule I to Schedule III. Sklamberg told Medscape that although President Biden's directive for the HHS and U.S. Attorney General to review how cannabis is scheduled under federal law "certainly made the agencies reconsider" rescheduling cannabis, rescheduling "was going to happen anyway." Sklamberg predicted that a proposed rule would be issued by mid-summer of 2024, because "agencies generally want